Chinese Journal of Dermatology ›› 2024, e20220578.doi: 10.35541/cjd.20220578
• Reviews • Previous Articles Next Articles
Zong Yangyongyi, Ma Chujun, Su Zhonglan
Received:
2022-08-18
Revised:
2023-08-30
Online:
2024-01-29
Published:
2024-03-01
Contact:
Su Zhonglan
E-mail:suzhonglan@jsph.org.cn
Supported by:
Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management[J]. Chinese Journal of Dermatology,2024,e20220578. doi:10.35541/cjd.20220578
[1] | 王宇, 杨斌. 银屑病与特应性皮炎的T细胞免疫失衡机制研究进展[J]. 皮肤性病诊疗学杂志, 2021,28(3):232⁃236. doi:10.3969/j.issn.1674⁃8468.2021.03.019. |
[2] | Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature[J]. Expert Opin Biol Ther, 2020,20(6):665⁃672. doi: 10.1080/14712598.2020.1727439. |
[3] | Driessen RJ, Berends MA, Boezeman JB, et al. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome[J]. Br J Dermatol, 2008,158(5):1098⁃1106. doi: 10.1111/j.1365⁃2133.2008.08514.x. |
[4] | Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52⁃week, open⁃label, phase 3 study (UNCOVER⁃J)[J]. J Dermatol, 2017,44(4):355⁃362. doi: 10.1111/1346⁃8138.13622. |
[5] | Liakos W, Toussi A, Le ST, et al. Anti⁃interleukin 23⁃based therapies may shift cutaneous immune responses: a case of new⁃onset contact dermatitis to carbamates after guselkumab for psoriasis[J]. Dermatitis, 2021,32(6):e113⁃e115. doi: 10.1097/DER.0000000000000765. |
[6] | Martinez⁃Mera C, González MA, Hospital M, et al. Isothiazolinones in paint as a cause of airborne contact dermatitis in a patient with psoriasis receiving anti⁃interleukin⁃17 therapy[J]. Contact Dermatitis, 2019,80(5):328⁃329. doi: 10.1111/cod.13203. |
[7] | Dhonncha EN,Razali Q,Roche L,et al. Erythroderma following ustekinumab therapy for psoriasis[J]. Br J Dermatol, 2018,179(S1):25. |
[8] | Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review[J]. J Eur Acad Dermatol Venereol, 2020,34(7):1440⁃1448. doi: 10.1111/jdv.16246. |
[9] | Bennett AN, Wong M, Zain A, et al. Adalimumab⁃induced asthma[J]. Rheumatology (Oxford), 2005,44(9):1199⁃1200. doi: 10. 1093/rheumatology/keh676. |
[10] | Chan JL, Davis⁃Reed L, Kimball AB. Counter⁃regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy[J]. J Drugs Dermatol, 2004,3(3):315⁃318. |
[11] | Pagan⁃Leon S, Werbel T, Montanez⁃Wiscovich M. Tumor necrosis factor inhibitor⁃induced eczematous eruption: a report of two cases and review of the literature[J]. Cureus, 2021,13(5):e15078. doi: 10.7759/cureus.15078. |
[12] | Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis[J]. Nat Commun, 2018,9(1):25. doi: 10.1038/s41467⁃017⁃02466⁃4. |
[13] | Psarras A, Antanaviciute A, Alase A, et al. TNF⁃α regulates human plasmacytoid dendritic cells by suppressing IFN⁃α production and enhancing T cell activation[J]. J Immunol, 2021,206(4):785⁃796. doi: 10.4049/jimmunol.1901358. |
[14] | Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti⁃interleukin 17 treatment of psoriasis: an emerging condition[J]. Br J Dermatol, 2019,181(3):604⁃606. doi: 10.1111/bjd.17779. |
[15] | Munera⁃Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab[J]. J Eur Acad Dermatol Venereol, 2019,33(1):e40⁃e42. doi: 10.1111/jdv.15156. |
[16] | Brembilla NC, Senra L, Boehncke WH. The IL⁃17 family of cytokines in psoriasis: IL⁃17A and beyond[J]. Front Immunol, 2018,9:1682. doi: 10.3389/fimmu.2018.01682. |
[17] | Karamanakos A, Vergou T, Panopoulos S, et al. Psoriasis as an adverse reaction to biologic agents beyond anti⁃TNF⁃α therapy[J]. Eur J Dermatol, 2021,31(3):307⁃317. doi: 10.1684/ejd. 2021.4056. |
[18] | Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis[J]. J Am Acad Dermatol, 2022,86(5):1080⁃1091. doi: 10.1016/j.jaad.2020.12.010. |
[19] | Weidinger S, Willis⁃Owen SA, Kamatani Y, et al. A genome⁃wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis[J]. Hum Mol Genet, 2013,22(23):4841⁃4856. doi: 10.1093/hmg/ddt317. |
[20] | Mendes Roncada EV, Brambilla VR, Freitas Filitto B, et al. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis[J]. Case Rep Dermatol, 2021,13(2):336⁃339. doi: 10.1159/000513467. |
[21] | Abe F, Mitsuyama S, Nagao E, et al. Atopic dermatitis⁃like eruption induced by two different biologics in a patient with psoriatic arthritis[J]. Acta Derm Venereol, 2019,99(13):1291⁃1292. doi: 10.2340/00015555⁃3321. |
[22] | Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report[J]. SAGE Open Med Case Rep, 2020,8:2050313X20904561. doi: 10.1177/2050313X20904561. |
[23] | Arevalo M, Fonseca E, Nespereira M, et al. Eczema⁃like reactions induced by tumor necrosis factor⁃α antagonist agents[J]. J Am Acad Dermatol, 2013,68(4, Supplement 1): AB180. doi: 10.1016/j.jaad.2012.12.743 |
[24] | Dumont⁃Berset M, Laffitte E, Gerber C, et al. Eczematous drug eruption after infliximab[J]. Br J Dermatol, 2004,151(6):1272⁃1273. doi: 10.1111/j.1365⁃2133.2004.06282.x. |
[25] | Reyn B, Hillary T, Gils A. Eczematous eruption after guselkumab treatment for psoriasis[J]. JAAD Case Rep, 2019,5(11):973⁃975. doi: 10.1016/j.jdcr.2019.09.005. |
[26] | Napolitano M, Gallo L, Patruno C, et al. Eczematous reaction to ixekizumab successfully treated with dupilumab[J]. Dermatol Ther, 2020,33(2):e13218. doi: 10.1111/dth.13218. |
[27] | Koschitzky M, Tan K, Noliza Encarnacion MR, et al. Eczematous reactions to psoriasis biologics treated with dupilumab: a case series[J]. JAAD Case Rep, 2021,11:29⁃32. doi: 10.1016/j.jdcr. 2021.03.006. |
[28] | Chicharro P, Rodríguez⁃Jiménez P, De la Fuente H, et al. Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti⁃IL⁃17 therapy[J]. J Allergy Clin Immunol Pract, 2020,8(10):3619⁃3621.e1. doi: 10.1016/j.jaip.2020.06.064. |
[29] | Lai F, Higgins E, Smith CH, et al. Morphologic switch from psoriasiform to eczematous dermatitis after anti⁃IL⁃17 therapy: a case series[J]. JAMA Dermatol, 2019,155(9):1082⁃1084. doi: 10.1001/jamadermatol.2019.1268. |
[30] | Peera M, Smith A. Palmoplantar pompholyx secondary to interleukin 17A inhibitor therapy for psoriasis: a case series[J]. JAAD Case Rep, 2021,13:46⁃48. doi: 10.1016/j.jdcr.2021.03. 052. |
[31] | Lai F, Pink A, Higgins E, et al. Phenotypic switch from psoriasis to eczema on anti⁃interleukin⁃17 therapy: a case series[J]. Br J Dermatol, 2019,181(S1):42⁃43. doi: 10.1111/bjd.17752 |
[32] | Eichhoff G. Secukinumab⁃induced pompholyx in a psoriasis patient[J]. Dermatol Online J, 2020,26(4):13030/qt3669k149. |
[33] | Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis[J]. Expert Rev Clin Immunol, 2019,15(11):1205⁃1214. doi: 10.1080/1744666X.2020.1672537. |
[34] | Damiani G, Pacifico A, Chu S, et al. Frequency of phototherapy for treating psoriasis: a systematic review[J]. Ital J Dermatol Venerol, 2022,157(3):215⁃219. doi: 10.23736/S2784⁃8671.21. 06975⁃3. |
[35] | Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema[J]. N Engl J Med, 2011,365(3):231⁃238. doi: 10.1056/NEJMoa1104200. |
[36] | Ono S, Honda T, Doi H, et al. Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin[J]. JAAD Case Rep, 2018,4(5):429⁃433. doi: 10.1016/j.jdcr. 2017.11.026. |
[37] | Park JW, Park SJ, Koh YG, et al. Dupilumab⁃induced palmoplantar psoriasis: is it true psoriasis?[J]. Dermatitis, 2022,33(3):e33⁃e35. doi: 10.1097/DER.0000000000000824. |
[38] | Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report[J]. Br J Dermatol, 2021,185(2):432⁃434. doi: 10.1111/bjd.20064. |
[39] | Beaziz J, Bouaziz JD, Jachiet M, et al. Dupilumab⁃induced psoriasis and alopecia areata: case report and review of the literature[J]. Ann Dermatol Venereol, 2021,148(3):198⁃201. doi: 10.1016/j.annder.2021.02.003. |
[40] | Imafuku S, Maeyama A. Remission of anti⁃tumor necrosis factor⁃α antibody⁃induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis[J]. J Dermatol, 2021,48(5):e240⁃e241. doi: 10.1111/1346⁃8138.15860. |
[41] | Wang YA, Rosenbach M. Successful treatment of refractory tumor necrosis factor inhibitor⁃induced palmoplantar pustulosis with tofacitinib: report of case[J]. JAAD Case Rep, 2020,6(2):115⁃118. doi: 10.1016/j.jdcr.2019.12.006. |
[42] | Licata G, Gambardella A, Tancredi V, et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib[J]. J Eur Acad Dermatol Venereol, 2022,36(2):e150⁃e152. doi: 10.1111/jdv.17705. |
[43] | Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis[J]. J Dermatolog Treat, 2020,31(1):33⁃40. doi: 10.1080/09546634.2019.1577549. |
[44] | Kvist⁃Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review[J]. Dermatol Ther (Heidelb), 2020,10(1):29⁃42. doi: 10.1007/s13555⁃019⁃00347⁃w. |
[45] | Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56⁃week data from the randomized controlled phase 3 SELECT⁃PsA 2 study[J]. Rheumatol Ther, 2021,8(2):903⁃919. doi: 10.1007/s40744⁃021⁃00305⁃z. |
[46] | Hayakawa M, Izumi K, Higashida⁃Konishi M, et al. Tocilizumab⁃induced psoriasis⁃like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case⁃based review[J]. Rheumatol Int, 2019,39(1):161⁃166. doi: 10.1007/s00296⁃018⁃4175⁃1. |
[47] | Cacabelos R, Naidoo V, Corzo L, et al. Genophenotypic factors and pharmacogenomics in adverse drug reactions[J]. Int J Mol Sci, 2021,22(24):13302. doi: 10.3390/ijms222413302. |
[1] | Chinese Association of Rehabilitation Dermatology, Working Group on Geriatric Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment, and rehabilitation of pruritus in the elderly (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(1): 1-8. |
[2] | Chinese Association of Rehabilitation Dermatology, Chinese Association of Photodynamic Therapy and Rehabilitation, Photodynamic Therapy Cooperation Center, Chinese Society of Dermatology . Expert consensus on clinical application of aminolevulinic acid photodynamic therapy in non-melanoma skin cancers (2025 edition) [J]. Chinese Journal of Dermatology, 2025, 58(1): 9-19. |
[3] | Liao Caihe, Wang Peiru, Wu Mingshun, Sun Xiaofei, Zhang Guolong, Wang Xiuli. Efficacy and safety of combination therapy with aminolevulinic acid photodynamic therapy in the treatment of facial basal cell carcinoma in the elderly: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 34-39. |
[4] | Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52. |
[5] | Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75. |
[6] | Wang Di, Zhang Ruijun, Kang Yuying. Pathogenesis and treatment of seborrheic dermatitis [J]. Chinese Journal of Dermatology, 2025, 58(1): 89-92. |
[7] | Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88. |
[8] | Wang Ruixia, Qu Yanlei, Ai Wenjin, Yan Lin, Qu Caijie, Shi Tongxin. A case of nonbullous neutrophilic lupus erythematosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 832-834. |
[9] | Xiang Xi, Zhang Lingyan, Zhong Lin, Gao Yi, Qiu Li. Multimodal ultrasound manifestations of port-wine stains and their application in efficacy assessment of photodynamic therapy [J]. Chinese Journal of Dermatology, 2024, 57(9): 801-806. |
[10] | Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829. |
[11] | Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742. |
[12] | Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769. |
[13] | Wei-Qi REN Ya-Ru ZOU Min PAN. Risk factors for secondary infection in patients with bullous pemphigoid [J]. Chinese Journal of Dermatology, 2024, 57(8): 770-772. |
[14] | Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727. |
[15] | Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression [J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664. |
|